Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen Will Help Upstream Validate Biomarkers

NEW YORK (GenomeWeb News) — NimbleGen will help Upstream Biosciences validate biomarkers, Upstream said today.
 
Under the agreement, NimbleGen will provide lab services including its whole-genome chromatin immunoprecipitation arrays to validate in silico binding-site predictions, Upstream said.
 
Upstream said it has filed five patents that would cover the use of genetic variations in certain regions that mark "various" cancers.
 
The NimbleGen studies will use samples of prostate and liver cancer to validate these proprietary markers," Upstream said.